Cancer researchers often focus on developing novel treatments or combining therapies in new ways, all with the goal of lengthening survival for patients. But some cancer research has a different goal: to reduce the...
In recent decades, the cancer research community has made great strides by bringing new, targeted, safer, and longer-lasting treatments to patients dealing with a variety of cancers. While this achievement is truly remarkable and...
Pancreatic cancer is projected to become the second leading cause of cancer mortality in the United States by 2030. The prognosis for this disease remains grim: The overall five-year survival rate is lower than...
September is Ovarian Cancer Awareness Month. It’s an apt time for the American Association for Cancer Research (AACR) Advances in Ovarian Cancer Meeting, scheduled for Sept. 13-16 in Atlanta. Ovarian cancer is a fairly rare...
When new cells are needed to replace old, worn-out cells in our organs and tissues, the DNA that encodes the blueprint for all cellular components from one cell must be replicated faithfully in each...
Policy plays a critical role in the fight against cancer, influencing the funding of cancer research and driving the approval of safe and effective anticancer therapies. With the increasing complexity of cancer-related policy issues,...
Last week, the U.S. Food and Drug Administration (FDA) approved the second of a new wave of molecularly targeted therapeutics that can be used to treat patients with any type of cancer provided their...
Cervical cancer patients may benefit from addressing any stress disorders they might have, as it could potentially improve their cancer prognosis.
The AACR Project Genomics Evidence Neoplasia Information Exchange (AACR Project GENIE) is a unique registry that aggregates, harmonizes, and links clinical-grade cancer genomic data with clinical outcomes from tens of thousands of cancer patients....
During late spring and early summer, the U.S. Food and Drug Administration (FDA) approved four new molecularly targeted therapeutics—alpelisib (Piqray), polatuzumab vedotin-piiq (Polivy), selinexor (Xpovio), and darolutamide (Nubeqa)—for treating certain patients with a wide...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More